Imaging agent developer ImaginAb has established a wholly owned subsidiary in Singapore.
ImaginAb Molecular Imaging (IMI) represents the first step in the firm's international expansion and will also mark a significant increase in its research capability, according to ImaginAb. IMI will provide preclinical molecular imaging services to both its U.S. parent company and select biopharma partnerships, including optical imaging and PET services, ImaginAb said.
